Join us for a dynamic live webinar designed to tackle critical clinical gaps in hepatocellular carcinoma (HCC) and cirrhosis management, featuring real-world data from a quality improvement initiative.

Join this live encore presentation of an interactive webinar, where expert cardiologists will explore the latest clinical evidence and guideline-driven strategies for managing RMI.

At the end of this session, learners can identify environmental interventions to mitigate behavior and compare the risks and benefits of different pharmacologic management strategies (AchEi, SSRI, sedatives, anti-psychotics).

Thinking about starting your own practice but not sure where to begin—or what services to include? This masterclass will show you how to build a private practice that fits your vision. If you're ready to break free, this session is for you.

In this webinar, expert faculty will set the stage by taking a deep dive into MF pathophysiology explaining the disease-modifying potential of novel therapies and how expanded treatment goals will help achieve deeper clinical and molecular responses.

Unlock your leadership potential with Stanford’s 4-month APP Leadership Certificate Program. Gain practical tools, coaching, and a supportive peer network to lead strategically, inspire teams, and drive change in patient care.

At the end of this session, learners can give examples of environmental interventions to reduce paranoia, recommend medicines most helpful to reduce behavioral symptoms of dementia and criticize a treatment plan to optimize medication use.

Innovative targeted and biomarker-directed therapies are changing the treatment landscape in HR+/HER2- metastatic breast cancer. Differentiating between mechanisms of action and adverse event profiles for these novel agents is crucial.

At the end of this session, learners can describe common sleep disorders affecting older adults, determine treatment options for sleep problems facing patients with dementia, and infer the benefit of sleep promotion on healthy aging.

Recent understanding of multiple sclerosis (MS) has increasingly emphasized the impact of silent progression on disability accumulation and long-term outcomes.